FDA InspectionBioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. – FDA Inspection, Dec 14, 2017
Record Details
This FDA Inspection record concerns BioMarin Pharmaceutical, Inc., with an inspection on December 14, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
- People
- Ashar P. Parikh
- Jolanna A. Norton (FDA Associated Person)
- Joslyn K. Brunelle (Company Rep)
- Ying Xin Fan (Issuing Officer)
ID · 294a4562-e09d-41ef-b5da-6e26860ddf6d
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1041169
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of BioMarin Pharmaceutical, Inc.
11| Date | Classification | Office | Project area |
|---|---|---|---|
| March 26, 2025 | Not classified | San Francisco District Office | |
| August 19, 2024 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 9, 2018 | Not classified | San Francisco District Office | |
| November 4, 2016 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| April 17, 2014 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Or discuss it with
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every BioMarin Pharmaceutical, Inc. document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA